Core Insights - Syra Health Corp. reported a 45% increase in total revenue for 2024, reaching 8.0millioncomparedto5.5 million in 2023, driven by growth in Population Health and Behavioral and Mental Health business units [5][8][6] - The company achieved significant operational efficiency, with Q4 2024 net losses nearly halved to 504,000from995,000 in Q4 2023, alongside a 39% reduction in operating expenses [15][5][6] - Continued momentum in securing new contracts and extensions is expected to drive sustainable growth, with a focus on higher-margin business units [5][7][6] Financial Performance - Population Health revenue more than doubled to 1.7millionin2024from715,000 in 2023, with Q4 2024 Population Health revenue increasing 285% year-over-year [5][13] - Adjusted EBITDA for 2024 was (3.7million),comparedto(2.8 million) in 2023, impacted by investments in the Syrenity clinical research study [11][12] - Gross profit margin decreased to 20.7% in 2024 from 25.6% in 2023, attributed to a reevaluation of lower-margin contracts [9][10] Operational Highlights - The company secured a one-year Healthcare Workforce contract valued at up to 1millionandatwo−yearcontractwiththeStateofMinnesota,enhancinghealthcareperformanceandpatientsatisfaction[5][6]−SyraHealth′smentalhealthproduct,Syrenity,isgainingtractionamongB2BandD2Ccustomers,withplansfornewproductenhancementsincludingtelehealth[7][6]−Thecompanyexpectslowdouble−digitpercentagerevenuegrowthfor2025,drivenbyhigher−marginPopulationHealthandBehavioralandMentalHealthunits[5][6]CashPosition−AsofDecember31,2024,SyraHealthhadcashof2.4 million and no long-term debt, indicating a stable liquidity position [5][12] - Total current assets decreased to 3.35millionin2024from4.78 million in 2023, while total liabilities reduced to 800,761from910,072 [17][18]